Immunosuppressive Tumor Microenvironment Mediated by
Myeloid-Derived Suppressor Cells and their Targeting
Time
9: 00 AM April 25, 2025 (Berlin Time, CEST)3: 00 PM April 25, 2025 (Beijing Time, CST)
Contact Us
Email: acrtjournal@sciexplor.comSpeaker
Professor Viktor Umansky, MD, PhD
Professor of Oncology, Faculty of Biosciences, University of Heidelberg, Germany.
Principal Investigator & Group Leader (Melanoma Immunotherapy), German Cancer Research Center (DKFZ) & University Medical Center Mannheim
Principal Investigator & Group Leader (Melanoma Immunotherapy), German Cancer Research Center (DKFZ) & University Medical Center Mannheim
Prof. Viktor Umansky is a leading expert in tumor immunology and melanoma immunotherapy, with a distinguished career spanning over four decades. After earning his PhD in 1982 at the Institute of Oncology in Kiev, Ukraine, he established himself as a pioneer in understanding tumor-induced immunosuppression and developing novel immunotherapeutic strategies.
At the German Cancer Research Center (DKFZ) and University Medical Center Mannheim, he leads the Melanoma Immunotherapy Group, where his team investigates immunosuppressive mechanisms in melanoma using a transgenic mouse model that closely mirrors human melanoma in genetics, pathology, and clinical progression. His groundbreaking work has elucidated the roles of:
• Chronic inflammation in shaping the melanoma microenvironment.
• Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) in tumor immune evasion.
• Tumor antigen-specific memory T cells in anti-tumor immunity.
• Nitric oxide-mediated apoptosis in lymphoma cells.
• Chronic inflammation in shaping the melanoma microenvironment.
• Myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) in tumor immune evasion.
• Tumor antigen-specific memory T cells in anti-tumor immunity.
• Nitric oxide-mediated apoptosis in lymphoma cells.
Prof. Umansky has published over 200 peer-reviewed articles in top-tier journals, including Nature, Nature Medicine, Nature Immunology, Journal of Clinical Investigation, Blood, PNAS, Cancer Research, and Journal for Immunotherapy of Cancer. His work has been instrumental in developing strategies to overcome immunosuppression in melanoma and enhance immunotherapy efficacy.
An active reviewer for prestigious journals and international grant agencies, Prof. Umansky continues to drive innovation in cancer immunology and ageing-related tumor progression - making him a key voice in the field.
Host
Prof. Rafael Solana
Department of Immunology, University of Cordoba, Cordoba, Spain.
Prof. Solana's research primarily focuses on immunosenescence - the gradual deterioration of the immune system associated with aging. His work delves into both innate and adaptive immunity, with particular emphasis on Natural Killer (NK) cells and their role in immune responses. His contributions have been instrumental in advancing the understanding of how aging affects immune function and the potential therapeutic interventions to mitigate these effects.
